More recently, the use of IL-17 pathway-blocking monoclonal antibodies (mAbs) in patients with psoriasis and inflammatory bowel disease (IBD) has been associated with the development in some patients with mild, treatment-responsive OPC, but not CMC. The gene discussed is IL17A; the disease is inflammatory bowel disease.